Denali Therapeutics Inc Capital Reinvestment Ratio
Denali Therapeutics Inc capital reinvestment ratio. Denali Therapeutics Inc (DNLI) has a Capital Reinvestment Ratio of 0.00x as of December 2020, meaning it reinvests 0% of its operating cash flow ($513.91 Million) in capital expenditures ($1.19 Million). Check total reinvestment intensity of Denali Therapeutics Inc to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Denali Therapeutics Inc (2018–2020)
Capital reinvestment ratio of Denali Therapeutics Inc from 2018 to 2020. This chart tracks Denali Therapeutics Inc's Capital Reinvestment Ratio across 2 annual periods. Also explore DNLI shareholders equity momentum to track the company's year-over-year net asset growth rate.
Denali Therapeutics Inc Capital Reinvestment Ratio by Year (2018–2020)
Denali Therapeutics Inc capital reinvestment ratio by year from 2018 to 2020. For the full cash flow conversion analysis, see how efficiently does Denali Therapeutics Inc generate cash.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2020 | 0.01x | $416.15 Million | $3.10 Million | ▼ -89.0% |
| 2018 | 0.07x | $50.12 Million | $3.39 Million | — |